Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

NCT00583622 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Ovarian Cancer

Interventions

DRUG: Bevacizumab
DRUG: Carboplatin
DRUG: Docetaxel
DRUG: Gemcitabine
DRUG: Melphalan
PROCEDURE: Stem Cell Transplant

Sponsor

M.D. Anderson Cancer Center